Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Aug 27;29(9):2358–2365. doi: 10.1038/s41591-023-02526-x

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2023

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 1 — a,b, There was no evidence of heterogeneity in the effects of semaglutide compared to placebo on the dual primary endpoints of KCCQ-CSS (a) or body weight (b). Data are point estimates and 95% CIs. Analyses using the intention-to-treat principle employ an F-test for interaction and a Wald test for treatment effect within BMI subgroups, with 1,000 imputations using Rubin’s rule. Analyses using on-treatment data employ an F-test for interaction and a t-test for treatment effect within BMI subgroups. P values are two-sided. ETD, estimated treatment difference.